Do Professional Development Programs for Maintenance of Certification (MOC) Affect Quality of Patient Care?

James M. Galliher, PhD, Brian K. Manning, MPH, Stephen M. Petterson, PhD, L. Miriam Dickinson, PhD, Elias C. Brandt, BS, Elizabeth W. Staton, MSTC, Robert L. Phillips, MD, MSPH, and Wilson D. Pace, MD

**Objective:** The objective of this study was to examine the relationship between physicians' completion of American Board of Family Medicine (ABFM) Maintenance of Certification (MOC) modules and the quality of medical care delivered.

**Methods:** Physicians from the Electronic National Quality Improvement and Research Network (eNQUIRENet) were enrolled. Data from their electronic health records were compared before and after they completed one or more MOC modules for family physicians (Self-Assessment Module [Part II MOC] and Performance in Practice Module [Part IV MOC]; SAM/PPM). Process data and other quantitative clinical measures for all adult patients with a diagnosis of type 2 diabetes were gathered from each study physician. General linear mixed effects models were used to analyze data before and after the MOC modules, adjusting for clustering of patients within physicians.

**Results:** Physicians participating in SAM/PPM activities demonstrated greater improvements over time in 11 of 24 measures in process and intermediate outcome measures related to type 2 diabetes care compared with non-SAM/PPM participants. All groups demonstrated improvements over time.

**Conclusion:** Participation in SAM/PPM activities is associated with greater improvements in care, but the association between activity undertaken and specific improvements is difficult to demonstrate. (J Am Board Fam Med 2014;27:19–25.)

**Keywords:** Certification, Diabetes Mellitus, Quality of Health Care, Training
This retrospective pilot study investigated the ability to demonstrate an effect of 2 specific MOC modules for family physicians—the Self-Assessment Module (SAM) from Part II MOC and the Performance in Practice Module (PPM) from Part IV MOC—on the quality of care delivered by family physicians to their patients. The study focused on study physicians’ patients with an established diagnosis of type 2 diabetes mellitus. In so doing, we also assessed the feasibility of obtaining and using these electronic data to investigate such questions and highlighted issues needing attention in larger systematic investigations.

Methods
This study used the Electronic National Quality Improvement and Research Network (eNQUIRENet), a subnetwork of the American Academy of Family Physicians (AAFP) National Research Network, previously named the Distributed Ambulatory Research in Therapeutics Network (DARTNet). eNQUIRENet is a network of medical organizations currently representing more than 2500 clinicians (45% family physicians) and 3 million patients. EHR data from geographically and organizationally separate databases are linked in a manner such that one query may access separate databases and return results while conforming to individual organization’s privacy and confidentiality standards.3,4

Recruitment of Study Physicians
Family physicians were recruited from eNQUIRENet. At the start of the project in March 2010, the network included 28 organizations with more than 1500 clinicians (approximately 60% family physicians) and more than 1000,000 patients.5 Our goal was to recruit 90 to 120 physicians, or 30 to 40 doctors per each of 3 study groups (described below).

Physicians were recruited from 23 of 28 eNQUIRENet organizations; 5 organizations had administrative or technical reasons precluding their participation. Recruitment occurred through a single contact at each organization. Written informed consent was required of physicians agreeing to participate. We clarified with each organization’s contact person how best to invite their family physicians into the study. Some organizations allowed project staff to directly contact their physicians by mail, E-mail, or phone, whereas others made these contacts themselves by informing their physicians about this research opportunity. Physician recruitment occurred June 17 through August 31, 2010.

Matching DARTNet Study Physicians to the ABFM Database
The ABFM MOC database identifies the topic and completion date of each SAM or PPM completed by ABFM diplomates. Using the first and last names of these diplomates, we matched the ABFM MOC database to the study physicians. Differences in the spelling of names or name changes were hand-edited to obtain a 100% match.

Obtaining SAM/PPM Completion Data from the ABFM Database
The information related to ABFM SAM and/or PPM participation was used to classify each study doctor into 1 or 3 mutually exclusive study groups:

1. Physicians completing a SAM and/or PPM in diabetes from January 1, 2007, to December 31, 2009 (at least some of these physicians also completed a SAM and/or PPM in a topic other than diabetes during this same period);
2. Physicians completing a SAM and/or PPM in a topic other than diabetes during 2007 to 2009; and
3. Physicians not completing either a SAM or PPM; these physicians’ ABFM records reported no completion of a SAM/PPM during this period.

For physicians with ≥2 SAMs/PPMs in diabetes (group 1) or some other topic (group 2), their program completion date reflected the most recent module completed. Physicians not completing a SAM/PPM during this period were assigned the median date for the diabetes cohort (October 2, 2008) for purposes of EHR data draws and analyses. We used the completion date of doctors’ most recent SAM or PPM (groups 1 and 2) as the last date of the period before the SAM/PPM. The completion date established the periods before and after the modules for each physician. To illustrate using a doctor’s completion date of July 13, 2009:

1. Date for start of period before the modules: July 14, 2008.
2. Date for end of period before the modules: July 13, 2009.
Date for start of period after the modules: July 14, 2009.

Date for end of period after the modules: July 13, 2010.

**Identification of Applicable Study Patients**

Each patient within a study physician’s practice who was (1) at least 18 years of age at the start of their study doctor’s period before the module and (2) had a diagnosis of type 2 diabetes before the start of their study doctor’s period before the module was included in the analysis.

**Identification and Abstraction of Study Patient Data**

The clinical data obtained for this study are shown in Table 1. Patients were attributed to study physicians either through the EHR or using an algorithm based on either a plurality of visits during the study period or on their initial visit. All patients used for this analysis were required to have at least one visit during the period after the intervention. A given study patient may also have seen another doctor during the study period.

**Developing Guideline Concordance Measures**

Quality of care delivered by physicians to patients with type 2 diabetes mellitus was tied to clinical guidelines recommended by the American Diabetes Association. Quantitative outcome measures were converted to dichotomous outcomes as being either concordant or not concordant with recommended clinical guidelines. These measures were converted to process measures (eg, dates on which a given test/examination was performed relative to clinical recommendations) unrelated to the actual quantitative clinical measure. Dichotomous clinical measures (angiotensin-converting enzyme [ACE]/angiotensin receptor blocker [ARB] usage and foot examination) were treated as both process and intermediate patient outcomes (yes/no).

Individual measures were combined into 2 composite concordance measures: (1) process outcome concordance, based on the performance of an activity, and (2) intermediate patient-outcome concordance, based on the actual clinical measure except when the process was also an outcome, such as performing a foot examination.

The values for each composite concordance measure varied from 0 (no patient guideline concordance across the 6 individual items) to 6.0 (complete patient guideline concordance). When expressed as proportions, these values varied from 0.0 (0 of 6 items concordant) to 1.0 (6 of 6 items concordant).

**Statistical Analysis**

Descriptive statistics (means, standard deviations, proportions, frequency distributions) were generated for patient sociodemographic measures, diabetes process of care, and clinical outcomes. General (generalized) linear mixed effects regression models, adjusting for patient age and sex, were used to examine differences in outcomes over time by group. Patient and physician random effects were included to adjust for clustering of observations within patients and clustering of patients within physicians. For each patient-level outcome, regression models included an indicator variable for (1) period before or after completion of the module, (2) physician group (the 3 groups of study doctors described earlier), and (3) an interaction term between the period and physician group. Although there was insufficient variability to include practice as a random effects, simulation studies with a 3-level data structure indicate less bias in param-

---

**Table 1. Clinical Process and Intermediate Patient Outcomes for the Before and After Periods Obtained for Patients of DARTNet Study Physicians**

<table>
<thead>
<tr>
<th>Individual Clinical Measures</th>
<th>Outcome Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Hemoglobin A1C</td>
<td>Every 12 months</td>
</tr>
<tr>
<td>1A. Process outcome (date)</td>
<td>Every 12 months</td>
</tr>
<tr>
<td>1B. Intermediate patient outcome (level)</td>
<td>&lt;8%</td>
</tr>
<tr>
<td>2. Blood pressure (systolic and diastolic)</td>
<td>Every 12 months</td>
</tr>
<tr>
<td>2A. Process outcome (date)</td>
<td>Every 12 months</td>
</tr>
<tr>
<td>2B. Intermediate patient outcome (level)</td>
<td>Systolic &lt;140, diastolic &lt;90</td>
</tr>
<tr>
<td>3. Low-density lipoprotein cholesterol</td>
<td>Every 12 months</td>
</tr>
<tr>
<td>3A. Process outcome (date)</td>
<td>Every 12 months</td>
</tr>
<tr>
<td>3B. Intermediate patient outcome (level)</td>
<td>&lt;100 mg/dL</td>
</tr>
<tr>
<td>4. Protein-to-creatinine ratio</td>
<td>Every 12 months</td>
</tr>
<tr>
<td>4A. Process outcome (date)</td>
<td>Every 12 months</td>
</tr>
<tr>
<td>4B. Intermediate patient outcome (level)</td>
<td>&lt;30 mg/mmol</td>
</tr>
<tr>
<td>5. Angiotensin-converting enzyme and angiotensin receptor blocker</td>
<td>Every 12 months</td>
</tr>
<tr>
<td>5A. Process outcome (date)</td>
<td>Every 12 months</td>
</tr>
<tr>
<td>5B. Intermediate patient outcome (date)</td>
<td>Every 12 months</td>
</tr>
<tr>
<td>6. Albumin-to-creatinine ratio</td>
<td>Every 12 months</td>
</tr>
<tr>
<td>6A. Process outcome (date)</td>
<td>Every 12 months</td>
</tr>
<tr>
<td>6B. Intermediate patient outcome (date)</td>
<td>&lt;30 mg/dL</td>
</tr>
</tbody>
</table>

3. Date for start of period after the modules: July 14, 2009.

4. Date for end of period after the modules: July 13, 2010.
eter estimates using a 2-level model ignoring the third level than for a 2-level model ignoring the second level.7 Thus we elected to include physician rather than practice as a random effect. In addition, these approaches can accommodate some single-tons and small (ie, <5 patients) lower-level sample sizes8 if the number of small samples is small relative to the total number of upper-level units. In this study there were only 2 physicians with fewer than 5 patients. All estimates are shown at the means for age and sex (average age, 61 years; 52% female). This project was approved by the AAFP Institutional Review Board.

Table 2. DARTNet Physician Study Groups and Eligible Patients at Before and at After Completion of SAM/PPM Periods

<table>
<thead>
<tr>
<th>Study Group</th>
<th>Doctors (n)</th>
<th>Patients No. Mean (SD) Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes SAM/PPM*</td>
<td>17</td>
<td>1169 68.7 (53.2) 1–163</td>
</tr>
<tr>
<td>Nondiabetes SAM/PPM</td>
<td>20</td>
<td>1345 67.2 (79.5) 5–364</td>
</tr>
<tr>
<td>No SAM or PPM†</td>
<td>39</td>
<td>2163 55.5 (50.0) 11–196</td>
</tr>
<tr>
<td>Totals</td>
<td>76</td>
<td>4677 61.5 (59.3) 1–364</td>
</tr>
</tbody>
</table>

*There were an additional 3 doctors in this group who were excluded from analysis because of a lack of any eligible patients. †There were an additional 7 doctors in this group who were excluded from analysis because of a lack of any eligible patients. SAM/PPM, Self-assessment Module/Performance in Practice Module.

Results

Recruitment Results

During the 10-week recruiting period, 86 family physicians from 16 practices enrolled (mean, 5.4; median, 2.5; range, 1–19 doctors per practice). We are not able to estimate a response rate since we do not know the number of family physicians actually invited to participate. Although 86 physicians enrolled, 10 (12%) were new to their practice and did not have patients who met the eligibility criteria related to timing of patient visits. Our final numbers were 76 doctors from 15 eNQUIRENet practices.

Doctors and their eligible patients by study group are shown in Table 2. Both SAM/PPM groups had roughly the same number of doctors (17 and 20, or 49%), while the other 39 doctors (51%) had neither a SAM nor PPM. Table 2 also shows the number of eligible patients for analysis (n = 4677). The differences in the average number of patients per physician cohort (55.5–68.7) was not statistically significant (P = .66); however, the standard deviation within each cohort was quite large (Table 2).

Tables 3 and 4 show before and after estimates for process of care, intermediate outcomes, and composite outcomes. When physicians from the type 2 diabetes mellitus SAM/PPM group were compared with those with no SAM/PPM, the former showed statistically greater improvement from

Table 3. Process Outcomes

<table>
<thead>
<tr>
<th>Group</th>
<th>Time</th>
<th>Foot Exam</th>
<th>ACE</th>
<th>Hemoglobin A1C Check</th>
<th>BP check</th>
<th>LDL Check</th>
<th>Albumin-to-Creatinine Ratio Check</th>
<th>Comp LP* (Average Score)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Diabetes</td>
<td>Before</td>
<td>9.20</td>
<td>15.10</td>
<td>49.44</td>
<td>61.30</td>
<td>49.40</td>
<td>12.97</td>
<td>1.99</td>
</tr>
<tr>
<td></td>
<td>After</td>
<td>19.40</td>
<td>24.90</td>
<td>70.70</td>
<td>84.80</td>
<td>68.50</td>
<td>25.97</td>
<td>2.96</td>
</tr>
<tr>
<td></td>
<td>Absolute difference</td>
<td>10.20</td>
<td>9.80</td>
<td>21.26</td>
<td>23.50</td>
<td>19.10</td>
<td>13.00</td>
<td>0.97</td>
</tr>
<tr>
<td></td>
<td>P value†</td>
<td>.0024</td>
<td>.0003</td>
<td>&lt;.0001</td>
<td>.9215</td>
<td>.8238</td>
<td>.1713</td>
<td></td>
</tr>
<tr>
<td>2. Other</td>
<td>Before</td>
<td>4.90</td>
<td>24.80</td>
<td>38.90</td>
<td>58.30</td>
<td>37.10</td>
<td>16.11</td>
<td>1.80</td>
</tr>
<tr>
<td></td>
<td>After</td>
<td>14.70</td>
<td>18.10</td>
<td>73.80</td>
<td>84.20</td>
<td>72.80</td>
<td>37.82</td>
<td>3.02</td>
</tr>
<tr>
<td></td>
<td>Absolute difference</td>
<td>9.80</td>
<td>-6.70</td>
<td>34.90</td>
<td>25.90</td>
<td>35.70</td>
<td>21.71</td>
<td>1.22</td>
</tr>
<tr>
<td></td>
<td>P value†</td>
<td>.0007</td>
<td>&lt;.0001</td>
<td>&lt;.0001</td>
<td>&lt;.0001</td>
<td>&lt;.0001</td>
<td>&lt;.0001</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>3. None</td>
<td>Before</td>
<td>3.70</td>
<td>19.30</td>
<td>58.40</td>
<td>65.70</td>
<td>51.20</td>
<td>18.90</td>
<td>2.18</td>
</tr>
<tr>
<td></td>
<td>After</td>
<td>18.70</td>
<td>21.40</td>
<td>79.70</td>
<td>82.60</td>
<td>70.50</td>
<td>32.31</td>
<td>3.06</td>
</tr>
<tr>
<td></td>
<td>Absolute difference</td>
<td>15.00</td>
<td>2.10</td>
<td>21.30</td>
<td>16.90</td>
<td>19.30</td>
<td>13.41</td>
<td>0.88</td>
</tr>
</tbody>
</table>

Data are percentages unless otherwise indicated.
*Comp LP is the average of the sum of all measures at the patient level (possible score of 0–6).
†For diabetes (group 1) vs. none (group 3).
‡For other (group 2) vs. none (group 3).
ACE, angiotensin-converting enzyme; BP, blood pressure; LDL, low-density lipoprotein.
the period before to the period after the program
($P < .01$) for ACE/ARB use, blood pressure (BP)
checks, and BP control. The type 2 diabetes mel-
litus group demonstrated smaller improvement for
performance of foot exams, although the final ab-
solute percentage of concordance was not different.
The composite intermediate outcome measure in-
dicated significantly greater improvement in the
SAM/PPM group as well ($P = .0048$).

In either process or outcome variables, when
physicians from the other SAM/PPM group were
compared with those with no SAM/PPM, the for-
mer showed statistically greater improvement ($P <
.01$) in ACE/ARB use, BP checks, low-density li-
oprotein (LDL) checks, albumin-to-creatinine ratio
checks, and the composite process of care score.
The other SAM/PPM group demonstrated greater
process improvement for intermediate outcomes
for BP, LDL, and microalbuminuria. These physi-
cians showed less improvement in foot exams and
an actual decline in ACE/ARB use.

Overall, of the 14 statistically significant com-
parisons in both measurement approaches, 11
showed greater improvements in patient concor-
dance from the period before to the period after the
module for one of the SAM/PPM groups compared
with the control group with no SAM/PPM pro-
gram completion (see Tables 3 and 4). Sensitivity
analyses varying the patient attribution approach
and varying the mixed effects models were con-
ducted, with similar results (data not shown), al-
though some measures lost significance when cor-
rected for multiple comparisons. Overall, all groups
improved over time in most measures.

### Discussion

To our knowledge, this is the first study to system-
atically investigate the associated effect of 2 specific
professional development programs required for
MOC—namely, SAM from Part II MOC and PPM
from Part IV MOC—on the quality of care deliv-
ered by family physicians. The results support
the concept of some impact on some aspects of diabetes
care quality as a result of the MOC process, al-
though this improvement seems to occur on a back-
drop of temporal trends for improved care. There
was considerable variation in specific concordance
measures, whether process or intermediate out-
comes, from a low of 3.5% of foot examination
concordant at baseline in the no SAM/PPM group
to a high of 97.4% of patients concordant for BP
measurement in the period after testing. The BP
finding is likely to be inflated by the fact that
patients were required to have at least one visit in
the period after intervention and BP is checked at
virtually all primary care visits.

The majority of the significant between-group
differences based on change in underlying perfor-
ance before and after the intervention favored the
groups that had taken one or more SAMs or com-
pleted a PPM. The finding that the group without

---

### Table 4. Intermediate Outcomes

<table>
<thead>
<tr>
<th>Group</th>
<th>Time</th>
<th>Hemoglobin A1C</th>
<th>BP</th>
<th>LDL</th>
<th>Albumin-to-Creatinine Ratio</th>
<th>Comp LI* (Average Score)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Diabetes</td>
<td>Before</td>
<td>22.5</td>
<td>54.7</td>
<td>33.7</td>
<td>10.2</td>
<td>1.46</td>
</tr>
<tr>
<td></td>
<td>After</td>
<td>33.2</td>
<td>76.6</td>
<td>50.8</td>
<td>20.5</td>
<td>2.26</td>
</tr>
<tr>
<td>Absolute difference</td>
<td>10.5</td>
<td>21.9</td>
<td>17.1</td>
<td>10.3</td>
<td>0.80</td>
<td></td>
</tr>
<tr>
<td>$P$ value‡</td>
<td>.3417</td>
<td>&lt;.0001</td>
<td>.1702</td>
<td>.7982</td>
<td>.0048</td>
<td></td>
</tr>
<tr>
<td>2. Other</td>
<td>Before</td>
<td>20.7</td>
<td>49.3</td>
<td>26.0</td>
<td>11.3</td>
<td>1.37</td>
</tr>
<tr>
<td></td>
<td>After</td>
<td>34.3</td>
<td>74.0</td>
<td>47.9</td>
<td>27.4</td>
<td>2.17</td>
</tr>
<tr>
<td>Absolute difference</td>
<td>13.6</td>
<td>24.7</td>
<td>21.9</td>
<td>16.1</td>
<td>0.79</td>
<td></td>
</tr>
<tr>
<td>$P$ value‡</td>
<td>.5043</td>
<td>&lt;.0001</td>
<td>.0001</td>
<td>.0008</td>
<td>.0504</td>
<td></td>
</tr>
<tr>
<td>3. None</td>
<td>Before</td>
<td>29.1</td>
<td>57.0</td>
<td>32.8</td>
<td>13.8</td>
<td>1.56</td>
</tr>
<tr>
<td></td>
<td>After</td>
<td>41.5</td>
<td>71.3</td>
<td>47.1</td>
<td>24.5</td>
<td>2.25</td>
</tr>
<tr>
<td>Absolute difference</td>
<td>12.4</td>
<td>14.3</td>
<td>14.3</td>
<td>10.7</td>
<td>0.69</td>
<td></td>
</tr>
</tbody>
</table>

Data are percentages unless otherwise indicated.
*Comp LI is the average of the sum of all measures at the patient level (possible score of 0–4).
†Diabetes (group 1) vs. none (group 3).
‡Other (group 2) vs. none (group 3).
BP, blood pressure; LDL, low-density lipoprotein.
a type 2 diabetes mellitus SAM/PPM improved on more diabetes measures than the group with a type 2 diabetes mellitus SAM/PPM is interesting. One interpretation could be a lack of effect of the SAM/PPM process. Another possible interpretation is that many of the measures of interest appear in other SAM/PPM activities; for instance, LDL and BP control are components of the cardiovascular SAM, and use of ACE inhibitors in patients with diabetes is a component of the hypertension SAM. Thus, it is likely that there could be an interaction of effects across MOC activities for these types of measures. If this is the case, these should be seen as positive phenomena since overall patient health is the final goal of MOC activities.

There is a concern among some continuing medical education providers that physicians attend continuing medical education activities in areas they are already interested in and better at. Thus, continuing medical education may have lesser impact on the lowest performing providers. In this project the patients in the type 2 diabetes mellitus SAM/PPM group started higher in 5 of 6 measures compared with the group with no SAM/PPM on clinical concordance (process and intermediate patient outcomes). These findings support the concern that physicians tend to take continuing medical education in areas where they are already relatively better providers of care.

**Study Limitations**

This pilot study has a number of limitations.

**Number of Study Doctors**

First, we had a limited number of family physicians responding to our invitation for the study, and thus we did not meet our initial goal of at least 30 doctors per each of 3 study groups. The reduced number of physicians per the 2 SAM/PPM study groups may have hindered our ability to find statistical significant differences because of reduced power. Physicians may continue to be wary of having their care examined at this level, even though no physician-identifying data were provided either to the ABFM or to a physician’s clinical organization. Because we had to approach each eNQUIRENet organization contact to recruit individual physicians, we have no way of knowing the number of potentially eligible family physicians that actually received a study invitation. Thus we do not know the response rate or how representative the study doctors (and their practice patterns) compare with the overall population of eNQUIRENet physicians. Physician participation required signing a short consent form. Physicians were paid a nominal amount for their time to review the consent form. Thus physician burden for entry into this study was low.

**Generalizability of Study Results**

Another limitation is related to the generalizability of study results. As is the case with most practice-based network studies, the doctors self-selected into the study. Thus we do not know how representative the study doctors (and their practice patterns) are compared to the overall population of US family physicians. Previous evaluations of differences between AAFP National Research Network physicians’ self-reported practice patterns and randomly selected AAFP members have not demonstrated differences, although physicians in eNQUIRENet were not included in those analyses, limiting extension to this study.

**Assignment of Eligible Patients to Study Doctors**

Another limitation to any analysis of physician performance relates to attribution strategies. Some, but not all, clinical organizations link patients and clinicians in their EHR. Even when assignment is clear in the EHR, there is generally no date attached to this assignment, and thus the accuracy of the data are not clear. Furthermore, an analysis of patient-provider visit frequency often does not align with the EHR assignment of the physician of record. Another approach to attribution for research purposes would be to have all practice doctors who had seen the patient during the study period assigned to a given patient. This overlapping of patients between cohorts would markedly complicate analysis and was not considered for this study. A common approach is to invoke the “plurality of patient visits” rule. Patients are assigned to the physician who saw the patients during the plurality of that patient’s visits during the study period. Patient assignment when ≥2 physicians are seen the same number of times can be handled in 3 ways: random assignment, assignment to the earliest physician, or assignment to the last physician seen. We studied 2 of these models: earliest physician seen and analysis limited to patients who saw the same physician in both study periods. These approaches had minimal effects on the results.
It is important to recognize that the results were analyzed at the physician level, and physicians in 2 or 3 of the MOC groups often existed in the same clinical organization. Thus a difference in cross-organizational quality improvement activities cannot explain the findings because physicians in all groups may have been exposed to the same quality improvement activities. These organizational activities may explain the overall improvement trends.

Conclusion
Despite these and other possible limitations, we found that it is quite feasible to (1) successfully match physicians with their ABFM records of program completion; (2) categorize these doctors into 3 mutually exclusive study groups; (3) identify and use multiple methods for assigning eligible patients to each study doctor (although we reported only one here); (4) obtain the needed patient clinical data from disparate EHRs; and (5) design, program, and describe the composite process and intermediate outcome concordance measures. The results support the concept that participation in MOC activities is associated with improvements of care, although the ability to track impact based on the particular MOC activities seems limited, at least in clinical areas with significant overlap of measurements.

The authors thank the eNQUIRENet health care organizations and physicians who agreed to participate in this investigation.

References

doi: 10.3122/jabfm.2014.01.130109